Raipur: The state viral research and diagnostic laboratory (VRDL) at the All India Institute of Medical Sciences (AIIMS), ...

The Centers for Disease Control and Prevention and the Department of Health and Human Services adopted Aug. 4 the Advisory ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency ...

Secretary Robert F. Kennedy Jr. said his department would slash funding for mRNA vaccine research and shift its focus to ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

The study found the program was more than 85% effective in reducing infant hospitalizations, emergency-room consultations and ...

Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, highlighting the need for targeted outreach programs.

Robert F. Kennedy Jr. claims to support “safe, effective vaccines” — but yanking $500 million of research funding on 22 key ...